Dabrafenib/Trametinib Approved for BRAF-Positive Anaplastic Thyroid Cancer

16:15 EDT 23 May 2018 | Cancer Networks

The approval is tremendous news and should have a profound impact on patients with the rare tumor, according to experts.

More From BioPortfolio on "Dabrafenib/Trametinib Approved for BRAF-Positive Anaplastic Thyroid Cancer"